Pazopanib confers a progression-free survival in a patient with ewing’s sarcoma/primitive neuroectodermal tumor of the lung

Abstract

Ewing’s sarcoma (ES)/primitive neuroectodermal tumors (PNETs) are highly malignant neoplasms that usually affect the bones and soft tissues in children and young adults. ES/PNET of the lung is very rare and is associated with a poor prognosis. We herein report a case of ES/PNET of the left lung in a 45-year-old man. He was treated with neoadjuvant chemotherapy and pneumonectomy, but unfortunately his disease recurred 1.5 months after surgery. He was started on pazopanib, which resulted in a five-month progressionfree survival. To our knowledge, this is the first demonstration of pazopanib efficacy in ES/PNET of the lung.